Overview

Akebia was founded in 2007 when the company in-licensed three preclinical programs from Procter & Gamble Pharmaceuticals (P&G). Akebia has an experienced development team that works closely with a network of world-renowned consultants and advisors. Based on data from studies conducted by P&G and additional preclinical and clinical work performed by Akebia, Akebia is focusing on developing three programs with significant market potential and relatively straightforward clinical pathways:

• AKB-6548 is a HIF2 stabilizer (HIF-PH inhibitor) in phase 2 clinical trials for chronic anemia. AKB-6548 promises to offer many advantages over products currently used to treat anemia, including an improved safety profile, oral dosing and lower costs.

• AKB-9778 is a small molecule Tie2 activator that inhibits HPTPß to maintain vascular integrity. This molecule is in late-stage preclinical development for the treatment of vascular leak.

• AKB-4924 is a HIF1 stabilizer (HIF-PH inhibitor) in pre-clinical development for wound healing and the treatment of irritable bowel disease (IBD).